Oncogenic NRG1 Fusions: A New Hope for Targeted Therapy in Pancreatic Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31164372.
- Also identified by DOI 10.1158/1078-0432.CCR-19-1280 and PMC identifier 6679796.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Approximately 8%-10% of pancreatic ductal adenocarcinoma cases are <i>KRAS</i> wild type. In a subset of these tumors, <i>NRG1</i> gene fusions have been identified as targetable oncogenic drivers, a discovery that highlights the importance of deep molecular characterization for <i>KRAS</i> wild-type pancreatic cancers and provides a novel treatment strategy in this disease.<i>See related article by Jones et al., p. 4674</i>.
Medical subject headings
- Carcinoma, Pancreatic Ductal
- Pancreatic Neoplasms